Sofiva Genomics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
March 27, 2020 at 03:20 am IST
Share
Sofiva Genomics Co.,Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was TWD 509.446 million compared to TWD 459.396 million a year ago. Operating income was TWD 66.722 million compared to TWD 54.066 million a year ago. Net income was TWD 62.671 million compared to TWD 47.350 million a year ago. Basic earnings per share was TWD 2.96 compared to TWD 2.26 a year ago. Diluted earnings per share was TWD 2.92 compared to TWD 2.23 a year ago.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
SOFIVA GENOMICS CO.,LTD. 
